Kymera Therapeutics, Inc. (KYMR)
86.59
+1.49
(+1.75%)
USD |
NASDAQ |
Apr 08, 14:08
Kymera Therapeutics Cash from Investing (TTM) : -521.06M for Dec. 31, 2025
Cash from Investing (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (TTM) Benchmarks
| Revolution Medicines, Inc. | 118.06M |
| Gilead Sciences, Inc. | -4.793B |
| Regeneron Pharmaceuticals, Inc. | -629.10M |
| Structure Therapeutics, Inc. | 90.03M |
| ACADIA Pharmaceuticals, Inc. | -302.56M |